In the Danish Biotech Weekly, we give you insights into the Danish biotech stocks. We follow the small and established ones at home and abroad. We keep you updated on their news flow including updates on clinical trials, acquisitions, insider trading, price targets, right issues, etc.
In the past week, Evaxion Biotech presented clinical data, Genmab announced net sales of Darzalex, and 2Curex published its annual report of 2022. 8 of the 20 listed, Danish biotech companies have published news the past week. 4 of the companies had a positive development in their share price for the week and 5 companies have had a positive share price performance year to date.
Company news the past week
Ascendis Pharma
No news the past week
No news the past week
Cessatech
April business update – the business strategy (LINK)
No news the past week
No news the past week
Evaxion Biotech
Evaxion announces promising clinical data for DNA-based personalized cancer immunotherapy EVX-02: Phase 1/2a trial met both primary and secondary endpoints (LINK)
Expres2ion
ExpreS2ion resolves on a directed issue of units to guarantors in connection with the completed rights issue (LINK)
Fluoguide
No news the past week
Genmab
argenx and Genmab Enter Partnership to Advance Antibody Therapies in Immunology and Oncology (LINK)
Genmab Announces Net Sales of DARZALEX® (daratumumab) for First Quarter of 2023 (LINK)
Genmab Announces Initial Resolution of Its Second Arbitration Under License Agreement with Janssen (LINK)
Gubra
No news the past week
Initiator Pharma
No news the past week
IO Biotech
No news the past week
Pila Pharma
No News the past week
Saniona
No news the past week
Scandion Oncology
No news past week
SynAct Pharma
SynAct Pharma announces program for the upcoming Capital Markets Day in Stockholm on May 5, 2023 (LINK)
ViroGates
No news past week
Zealand Pharma
Zealand Pharma launches long-term incentive program for Zealand’s Board of Directors, Corporate Management and employees for 2023 (LINK)
Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons (LINK)
Y-mAbs Therapeutics
Y-mAbs Announces Presentation of Naxitamab data at AACR (LINK)
2cureX
2cureX publishes the annual report for the fiscal year 2022 (LINK)
SELECTED CASES
SHARE PRICE DEVELOPMENTS
Most of the Danish Biotech stocks fell during last week. Thus, the average return was -4.5%. Only 4 of them had a positive return. Biosergen AB became the best performing stock followed by Zealand Pharma A/S. On the other hand, ViroGates A/S and Pila Pharma A/S became the worst performing Danish biotech stocks last week. Since the start of the year, most of the companies have been under pressure, while especially Saniona AB, Zealand Pharma A/S and Fluoguide AB have performed very well.
Read more about Fluoguide: The unique cancer treatment of the future – Today’s investment
